Alembic Pharmaceuticals Limited

NSEI:APLLTD Stock Report

Market Cap: ₹201.4b

Alembic Pharmaceuticals Valuation

Is APLLTD undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of APLLTD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: APLLTD (₹1024.65) is trading above our estimate of fair value (₹544.45)

Significantly Below Fair Value: APLLTD is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for APLLTD?

Key metric: As APLLTD is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for APLLTD. This is calculated by dividing APLLTD's market cap by their current earnings.
What is APLLTD's PE Ratio?
PE Ratio31.1x
Earnings₹6.47b
Market Cap₹201.41b

Price to Earnings Ratio vs Peers

How does APLLTD's PE Ratio compare to its peers?

The above table shows the PE ratio for APLLTD vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average51x
530019 Jubilant Pharmova
30.6x5.5%₹181.3b
CONCORDBIO Concord Biotech
61.1x26.9%₹200.3b
524558 Neuland Laboratories
68.9x33.9%₹192.8b
EMCURE Emcure Pharmaceuticals
43.5x25.3%₹246.8b
APLLTD Alembic Pharmaceuticals
31.1x21.5%₹201.4b

Price-To-Earnings vs Peers: APLLTD is good value based on its Price-To-Earnings Ratio (31.1x) compared to the peer average (51x).

Price to Earnings Ratio vs Industry

How does APLLTD's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
INDSWFTLAB Ind-Swift Laboratories
1.6xn/aUS$72.79m
524652 Ind-Swift
2xn/aUS$13.15m
No more companies available in this PE range
APLLTD 31.1xIndustry Avg. 32.7xNo. of Companies18PE020406080100+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: APLLTD is good value based on its Price-To-Earnings Ratio (31.1x) compared to the Indian Pharmaceuticals industry average (32.7x).

Price to Earnings Ratio vs Fair Ratio

What is APLLTD's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

APLLTD PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio31.1x
Fair PE Ratio42x

Price-To-Earnings vs Fair Ratio: APLLTD is good value based on its Price-To-Earnings Ratio (31.1x) compared to the estimated Fair Price-To-Earnings Ratio (42x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst APLLTD forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current₹1,024.65
₹1,161.92
+13.4%
12.6%₹1,412.00₹895.00n/a12
Nov ’25₹1,127.05
₹1,092.58
-3.1%
13.0%₹1,396.00₹837.00n/a12
Oct ’25₹1,191.95
₹1,092.17
-8.4%
13.0%₹1,396.00₹837.00n/a12
Sep ’25₹1,059.10
₹1,056.33
-0.3%
14.3%₹1,396.00₹837.00n/a12
Aug ’25₹1,212.50
₹985.08
-18.8%
9.9%₹1,229.00₹845.00n/a13
Jul ’25₹923.50
₹983.54
+6.5%
9.8%₹1,229.00₹845.00n/a13
Jun ’25₹923.10
₹980.31
+6.2%
10.1%₹1,229.00₹845.00n/a13
May ’25₹999.60
₹937.69
-6.2%
9.7%₹1,143.00₹770.00n/a13
Apr ’25₹1,008.95
₹901.08
-10.7%
7.3%₹1,023.00₹770.00n/a13
Mar ’25₹1,055.00
₹888.14
-15.8%
8.9%₹1,023.00₹720.00n/a14
Feb ’25₹955.55
₹769.67
-19.5%
13.0%₹915.00₹515.00n/a15
Jan ’25₹765.90
₹742.44
-3.1%
15.2%₹915.00₹515.00n/a16
Dec ’24₹751.15
₹742.44
-1.2%
15.2%₹915.00₹515.00n/a16
Nov ’24₹712.55
₹723.07
+1.5%
15.1%₹895.00₹515.00₹1,127.0515
Oct ’24₹784.45
₹715.33
-8.8%
14.9%₹895.00₹515.00₹1,191.9515
Sep ’24₹770.50
₹715.33
-7.2%
14.9%₹895.00₹515.00₹1,059.1015
Aug ’24₹775.50
₹598.20
-22.9%
9.0%₹704.00₹515.00₹1,212.5015
Jul ’24₹636.40
₹590.87
-7.2%
8.7%₹704.00₹515.00₹923.5015
Jun ’24₹548.85
₹586.94
+6.9%
8.7%₹704.00₹515.00₹923.1016
May ’24₹556.15
₹601.25
+8.1%
7.7%₹704.00₹540.00₹999.6016
Apr ’24₹496.35
₹603.44
+21.6%
7.3%₹704.00₹540.00₹1,008.9516
Mar ’24₹507.25
₹630.24
+24.2%
14.5%₹944.00₹550.00₹1,055.0017
Feb ’24₹539.65
₹674.63
+25.0%
14.1%₹944.00₹563.00₹955.5516
Jan ’24₹572.90
₹676.50
+18.1%
14.2%₹944.00₹563.00₹765.9016
Dec ’23₹594.60
₹682.75
+14.8%
13.4%₹944.00₹563.00₹751.1516
Nov ’23₹577.85
₹681.44
+17.9%
14.0%₹944.00₹538.00₹712.5516

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

IOL Chemicals and Pharmaceuticals

₹20.5b

Manufactures and sells pharmaceutical and chemical products in India and internationally.

IOLCP

₹348.90

7D

-11.3%

1Y

-16.9%

Solara Active Pharma Sciences

₹35.8b

Manufactures, produces, processes, formulates, sells, imports, exports, merchandises, distributes, trades in, and deals in active pharmaceutical ingredients (API) in India, Asia Pacific, Europe, North America, South America, and internationally.

SOLARAPP

₹458.00

7D

-3.8%

1Y

n/a

Caplin Point Laboratories

₹150.9b

Engages in the development, production, marketing, and export of generic pharmaceutical formulations and branded products in India.

CAPLIPOINT

₹1,988.75

7D

-1.2%

1Y

56.6%